A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Trial Profile

A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Aug 2017 Planned End Date changed from 1 Jul 2021 to 1 Jun 2021.
    • 17 Aug 2017 Planned primary completion date changed from 1 Jul 2021 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top